Verrica Pharmaceuticals/$VRCA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
Ticker
$VRCA
Sector
Primary listing
Employees
76
Headquarters
Website
VRCA Metrics
BasicAdvanced
$105m
-
-$1.31
1.49
-
Price and volume
Market cap
$105m
Beta
1.49
52-week high
$9.82
52-week low
$3.28
Average daily volume
42k
Financial strength
Current ratio
2.104
Quick ratio
1.752
Long term debt to equity
4.348
Total debt to equity
8.982
Interest coverage (TTM)
-2.37%
Profitability
EBITDA (TTM)
-13.058
Gross margin (TTM)
61.45%
Net profit margin (TTM)
-47.97%
Operating margin (TTM)
-36.39%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
-20.88%
Return on equity (TTM)
1,414.20%
Valuation
Price to revenue (TTM)
2.247
Price to book
6.56
Price to tangible book (TTM)
6.56
Price to free cash flow (TTM)
-5.915
Free cash flow yield (TTM)
-16.91%
Free cash flow per share (TTM)
-1.037
Growth
Revenue change (TTM)
417.63%
Earnings per share change (TTM)
-87.32%
3-year revenue growth (CAGR)
62.64%
3-year earnings per share growth (CAGR)
-39.59%
VRCA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs